

Rachel S Kerr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5860609/publications.pdf>

Version: 2024-02-01

37
papers

3,289
citations

361045

20
h-index

344852

36
g-index

39
all docs

39
docs citations

39
times ranked

7157
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1177-1188. | 13.9 | 699 |
| 2 | COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 1309-1316. | 5.1 | 473 |
| 3 | Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. <i>Lancet</i> , The, 2020, 395, 350-360. | 6.3 | 364 |
| 4 | Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 894-904. | 5.1 | 270 |
| 5 | Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 207-216. | 3.7 | 227 |
| 6 | Association analyses identify 31 new risk loci for colorectal cancer susceptibility. <i>Nature Communications</i> , 2019, 10, 2154. | 5.8 | 172 |
| 7 | 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2018, 19, 562-578. | 5.1 | 133 |
| 8 | Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1543-1557. | 5.1 | 129 |
| 9 | A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. <i>Scientific Reports</i> , 2015, 5, 10442. | 1.6 | 109 |
| 10 | A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYDand a putative role forENOSF1rather thanTYMS. <i>Gut</i> , 2015, 64, 111-120. | 6.1 | 93 |
| 11 | Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis. <i>European Journal of Cancer</i> , 2017, 84, 228-238. | 1.3 | 81 |
| 12 | Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. <i>International Journal of Cancer</i> , 2017, 140, 2701-2708. | 2.3 | 76 |
| 13 | Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 635-643. | 3.7 | 60 |
| 14 | Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 266-272. | 2.9 | 57 |
| 15 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 400-407. | 3.0 | 44 |
| 16 | Variation at 2q35 (<i>PNKD</i> and <i>TMBIM1</i>) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease. <i>Human Molecular Genetics</i> , 2016, 25, 2349-2359. | 1.4 | 37 |
| 17 | The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management. <i>Familial Cancer</i> , 2022, 21, 197-209. | 0.9 | 31 |
| 18 | 'Toxgnostics': an unmet need in cancer medicine. <i>Nature Reviews Cancer</i> , 2014, 14, 440-445. | 12.8 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci. <i>International Journal of Cancer</i> , 2018, 142, 540-546. | 2.3 | 26 |
| 20 | Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704. | 3.0 | 25 |
| 21 | 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-88. | 1.3 | 20 |
| 22 | SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1332-1338. | 2.9 | 19 |
| 23 | Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA1-LBA1. | 0.8 | 17 |
| 24 | Is sidedness prognostically important across all stages of colorectal cancer?. <i>Lancet Oncology</i> , The, 2016, 17, 1480-1482. | 5.1 | 15 |
| 25 | Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis. <i>Journal of Clinical Pathology</i> , 2015, 68, 1036-1039. | 1.0 | 14 |
| 26 | An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities. <i>Cancers</i> , 2021, 13, 1497. | 1.7 | 12 |
| 27 | The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial. <i>Journal of Surgical Oncology</i> , 2018, 117, 1043-1048. | 0.8 | 10 |
| 28 | Celecoxib for Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1257. | 3.8 | 9 |
| 29 | Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial. <i>Anticancer Research</i> , 2015, 35, 1641-5. | 0.5 | 9 |
| 30 | Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. <i>International Journal of Cancer</i> , 2021, 149, 1713-1722. | 2.3 | 7 |
| 31 | ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility studyâ€”PRECISE study. <i>Cancer Medicine</i> , 2019, 8, 6305-6314. | 1.3 | 6 |
| 32 | Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67. | 3.0 | 5 |
| 33 | Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 363-371. | 1.0 | 4 |
| 34 | Genetic variation in <i>ST6GAL1</i> is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. <i>International Journal of Cancer</i> , 2022, , . | 2.3 | 3 |
| 35 | Toxgnostics: predicting and preventing chemotherapy-induced side effects. <i>Personalized Medicine</i> , 2014, 11, 683-685. | 0.8 | 1 |
| 36 | Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3606-3606. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3540-3540. | 0.8 | 0 |